AOD-9604 Peptide Regulatory Status in Canada Health Canada Regulatory Status - Unapproved Investigational Compound AOD-9604 has never been authorized by Health Canada or any other major health authority worldwide for any human or veterinary indication
Combination Strategies for Enhanced Efficacy: For Inflammation: ALC + PEA 1,200 mg/day (demonstrated synergy in fibromyalgia)[5] ALC + Omega-3 fatty acids 2-4 g/day ALC + Curcumin 500-1,000 mg/day For Neuropathic Pain: ALC + Alpha-lipoic acid 600 mg/day (complementary metabolic support)[6] ALC + B vitamins (B1, B6, B12) for neurotrophic effects ALC + PEA for enhanced analgesic effect For Central Sensitization: ALC + PEA 1,200 mg/day (strong synergy demonstrated)[5] ALC + Magnesium 400-600 mg/day (complementary glutamate modulation) ALC + Low-dose naltrexone (complementary anti-sensitization mechanisms) For Oxidative Stress: ALC + Alpha-lipoic acid 600 mg/day ALC + N-acetylcysteine 600-1,200 mg/day ALC + CoQ10 100-300 mg/day For Mitochondrial Dysfunction: ALC + CoQ10 100-300 mg/day (complementary electron transport chain support) ALC + Alpha-lipoic acid 600 mg/day ALC + B vitamins (cofactors for mitochondrial enzymes) DOSING OVERVIEW Bioavailability: Oral bioavailability is low (14-18%) due to saturable intestinal absorption and extensive first-pass metabolism.[14][15] Despite low bioavailability, clinical efficacy is demonstrated at therapeutic doses
5 As described in the vitamin B 12 Dietary Fact Sheet from the National Institutes of Health (NIH), the recommended daily intake of vitamin B 12 ranges from 0.4 mcg in young infants to
In summary, consistent studies have fully elaborated the negative evidence (i.e., BPC 157 counteracted worsening effects induced by L-NAME) [11,29]
